Technical Analysis for ZIOP - ZIOPHARM Oncology Inc

Grade Last Price % Change Price Change
F 3.145 1.45% 0.05
ZIOP closed up 4.03 percent on Tuesday, May 11, 2021, on 88 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ZIOP trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.97%
Lower Bollinger Band Walk Weakness 0.97%
Outside Day Range Expansion 0.97%
Lower Bollinger Band Touch Weakness 0.97%
180 Bearish Setup Bearish Swing Setup 5.03%
Lower Bollinger Band Walk Weakness 5.03%
Oversold Stochastic Weakness 5.03%
Slingshot Bearish Bearish Swing Setup -2.19%
Lower Bollinger Band Walk Weakness -2.19%
Earnings Movers Other -2.19%
Older End-of-Day Signals for ZIOP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 1 hour ago
Down 1% about 1 hour ago
Up 1% about 1 hour ago
Rose Above Previous Day's High about 20 hours ago
Outside Day about 20 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ZIOPHARM Oncology Inc Description

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer. The company's portfolio of clinical-stage product candidates also includes ZIN-CTI-001, which is in Phase Ib clinical trial in patients with metastatic melanoma; ZIN-ATI-001, which is in Phase 1b clinical trial in patients with late-stage melanoma; Indibulin (ZIO-301), a novel, tubulin binding agent in Phase I/II clinical trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial-and hedgehog-targeted agent. In addition, it is developing oral capsule form of palifosfamide. The company has an exclusive channel partner agreement with Intrexon Corporation in which the company uses Intrexon Corporation technology directed towards in vivo expression of effectors in connection with the development of ZIN-CTI-001 and ZIN-ATI-001. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Melanoma Sarcoma Cancer Therapies Metastatic Melanoma Intrexon Metastatic Breast Cancer Mitochondria Neoplasms Soft Tissue Sarcoma Metastatic Small Cell Lung Cancer

Is ZIOP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.95
52 Week Low 2.06
Average Volume 1,914,438
200-Day Moving Average 3.24
50-Day Moving Average 3.68
20-Day Moving Average 3.29
10-Day Moving Average 3.22
Average True Range 0.23
ADX 18.23
+DI 15.84
-DI 24.85
Chandelier Exit (Long, 3 ATRs ) 2.97
Chandelier Exit (Short, 3 ATRs ) 3.56
Upper Bollinger Band 3.64
Lower Bollinger Band 2.93
Percent B (%b) 0.24
BandWidth 21.50
MACD Line -0.16
MACD Signal Line -0.15
MACD Histogram -0.007
Fundamentals Value
Market Cap 664.3 Million
Num Shares 214 Million
EPS 0.58
Price-to-Earnings (P/E) Ratio 5.39
Price-to-Sales 0.00
Price-to-Book 4.32
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.53
Resistance 3 (R3) 3.51 3.35 3.46
Resistance 2 (R2) 3.35 3.24 3.36 3.43
Resistance 1 (R1) 3.23 3.18 3.29 3.24 3.41
Pivot Point 3.07 3.07 3.10 3.08 3.07
Support 1 (S1) 2.94 2.96 3.01 2.96 2.79
Support 2 (S2) 2.78 2.89 2.79 2.77
Support 3 (S3) 2.66 2.78 2.74
Support 4 (S4) 2.67